Akouos, Inc. (AKUS)

$ 5.8
-0.25 (-4.13%)
-
Symbol AKUS
Price $ 5.8
Beta 0.000
Volume Avg. 0.13M
Market Cap 0.200B
Shares () -
52 Week Range 5.8-22.88
1y Target Est -
DCF Unlevered AKUS DCF ->
DCF Levered AKUS LDCF ->
ROE -26.06% Sell
ROA -24.97% Sell
Operating Margin -
Debt / Equity 16.09% Neutral
P/E -
P/B 0.78 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AKUS news


Dr. Emmanuel Simons M.B.A., Ph.D.
Healthcare
Biotechnology
Nasdaq Global Select

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.